1
Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy: Cancellous bone treated with collagenase and essentially free of blood cells. NuVasive, NuVasive, Jonathan Spangler, Jennifer Russell, June 11, 2013: US08460860 (2 worldwide citation)

A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic ...


2
Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy: Mesenchymal stem cells expressing TNF-alpha receptors. Osiris Therapeutics, McAndrews Held & Malloy, July 16, 2013: US08486695 (1 worldwide citation)

Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.


3
Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy: Cancellous bone treated with collagenase and essentially free of blood cells. Raymond J Lillie Esq, c o Carella Byrne Bain Gilfillan, November 8, 2007: US20070260326-A1

A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least a loosening agent, such as collagenase and/or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic ...


4
Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy: Mesenchymal stem cells expressing TNF-alpha receptors. Osiris Therapeutics, Carella Byrne Bain Gilfillan Cecchi, Stewart & Olstein, November 8, 2007: US20070258963-A1

Mesenchymal stem cells which express TNF-{acute over (α)} receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.


5
Michelle LeRoux Williams, Charles Randal Mills, Rodney Monroy, Robert A Zambon, Dayna Buskirk, Earl Fender: Cancellous bone treated with collagenase and essentially free of blood cells. Raymond J Lillie Esq, c o Carella Byrne Bain Gilfillan, October 23, 2008: US20080262633-A1

A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least one loosening agent, such as collagenase or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic c ...


6
Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy: Mesenchymal stem cells expressing tnf-a receptor. Mcandrews Held & Malloy, July 2, 2009: US20090169522-A1

Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.


7
Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy: Mesenchymal Stem Cells Expressing TNF-alpha Receptors. August 4, 2011: US20110189768-A1

Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.


8
Alla Danilkovitch, Diane Carter, Alicia Tyrell, Simon Bubnic, Michelle Marcelino, Rodney Monroy: Mesenchymal Stem Cells Expressing TNF-alpha Receptors. August 23, 2012: US20120214178-A1

Mesenchymal stern cells which express TNF-α receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.